Abbott Receives European Nod For Pediatric Heart Devices
Zacks Investment Research | Sep 18, 2019 07:57AM ET
Abbott Laboratories (NYSE:ABT) announced receiving approvals for two life-saving pediatric devices — the Masters HP 15mm rotatable mechanical heart valve and the Amplatzer Piccolo Occluder — in Europe. The devices have received the CE Mark, and are currently available in Europe and other countries that recognize CE Mark.
The new treatments are already available in the United States, and offer hope to young pediatric patients and their families when no other appropriate treatment options are available.
With the latest offerings to treat critical cases of babies and children born with common congenital heart defects, Abbott aims to improve its footprint in the global pediatric mechanical heart valve market.
Few Words on the Devices
The Masters valve is much smaller in size (15mm) and the company claims that it is the world's smallest mechanical heart valve. Mechanical heart valves are required in cases, where the heart valve tissues are significantly deformed or are damaged beyond repair. The mechanical valve resembles a healthy heart valve and regularizes blood flow through the heart with each heartbeat.
Amplatzer Piccolo (approved in the United States in January 2019) is a self-expanding wire-mesh device, which is inserted through a small incision in the leg and guided through vessels to the heart, where it is placed to seal the opening.
With Amplatzer Piccolo, most of the critically ill premature babies in the neonatal intensive care unit can be taken off the artificial respirator support soon after the minimally invasive procedure.
Significance of the Devices
Every year, around 36,000 babies are born with congenital heart defects (“CHD”) in the European Union alone. The Masters valve is expected to help doctors treat babies and toddlers, who require mitral or aortic heart valve replacement.
The Amplatzer Piccolo, which is smaller than a pea, can even be implanted in babies, who weigh less than a kilogram, to treat patent ductus arteriosus (PDA), which is a potentially life-threatening opening in the heart. Abbott believes that this device is the world’s first medical device that can be implanted even in premature babies.
Why the Approval is Important
Get The News You Want
To date, the only option available to doctors for treating issues of pediatric heart valve was to replace the damaged valve with a range of larger-sized valves. This could result in future complications.
Abbott believes that the two devices can help infants and children to live their fullest life.
With these approvals, the company aims to provide a dependable and corrective treatment solution, and subsequently healthy life to patients, who may be non-responsive to medical management and also pose an increased risk of corrective surgery. It believes that with these technological advancements, doctors can treat structural heart disease in pediatric patients who have limited options.
Given the huge potential for offering treatments to infants, these approvals have come at just the right time.
Industry Prospects
Per a report by Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.